Furthermore, we observed an enrichment of CD8+ T cells in LAG-3-positive BTC, which is consistent with previous findings in melanoma, where LAG-3-positive melanoma exhibited higher levels of CD8+ T cells and responded more effectively to treatments targeting either PD-1 alone or in combination with LAG-3 [39, 40]. This evidence concerns the gene PDCD1 and melanoma.